Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 August 2021 | Story André Damons | Photo André Damons
Dr Osayande Evbuomwan is a Senior Lecturer and medical specialist in nuclear medicine in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS).

The University of the Free State (UFS) Department of Nuclear Medicine has, for the first time, started using Lutetium 177 PSMA (Lu-177 PSMA) therapy for the treatment of metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer.

The UFS and the Free State province are now joining other South African universities, such as the University of Pretoria, the University of the Witwatersrand, and other provinces in using this method to treat MCRPC patients. 

Dr Osayande Evbuomwan, a Senior Lecturer and medical specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, says they have started treating their first MCRP patient (first cycle) with peptide receptor radionuclide therapy (PRRT) on 15 July. It is the first time that Lutetium 177 PSMA – a type of PRRT used for treating patients with MCRPC – has been used in the Free State. This method is used on MCRPC patients who are not eligible for chemotherapy or have failed first- or second-line chemotherapy.

Expertise and funds are now available for this treatment

Dr Evbuomwan was trained and exposed to this therapy at the University of the Witwatersrand during his registrar training in nuclear medicine. When he joined the UFS in 2019, he – with the always available help of the Head of Department, Dr Gerrit Engelbrecht – pushed for the therapy to be used in the department. 

“We in the Department of Nuclear Medicine are happy that expertise is now available and that some funds have been released for this treatment to commence. The index patient is very sick with MCRPC and was too sick to qualify for first-line chemotherapy. Each patient will need about four-six cycles for complete treatment. The patient is being treated in the Department of Nuclear Medicine at the Universitas Academic Hospital and Annex.” 

“We are hoping that he will be able to complete at least four cycles and respond well to the treatment. We believe that the ability to administer this treatment now is good news for the Free State, as the people of the Free State also deserve to be exposed to this level of treatment. We are hoping that the government will continue to provide more funds for more of these patients to be treated in our facility,” says Dr Evbuomwan.

It was budgeted to treat five patients (20 cycles), with each cycle (just the Lu-177 PSMA) costing more than R50 000. 

A googled image from the internet of a case before, during, and after completing the full course of therapy. The first image is before
treatment and the last image is after completing treatment, while the images in between are during treatment.
(Source: Google) 

Prostate cancer one of the leading causes of morbidity and mortality

Dr Evbuomwan says prostate cancer is one of the leading causes of morbidity and mortality in the world, including South Africa. When it progresses to the advanced stage of MCRPC, the prognosis becomes bad. 

Dr Evbuomwan explains that there are various conventional systemic therapies, including first- and second-line chemotherapy that could be used to treat patients at this bad stage. However, not all patients are fit for chemotherapy. The few who are fit, according to Dr Evbuomwan, usually end up failing the first-line chemotherapy, which has a lot of undesirable side effects and require long-stay hospital admissions. 

Only a few centres are able to offer second-line chemotherapy. So many of these patients end up suffering from prolonged bone pains before eventually dying from the disease.

PRRT is a targeted nuclear medicine therapy that offers the opportunity to deliver very high levels of radiation specifically to cancer cells, because these cancer cells express specific receptors to which certain peptides can bind. This specificity to cancer cells offers the advantage of providing lower doses of radiation and damage to normal organs and tissues, a characteristic that conventional therapies do not offer, explains Dr Evbuomwan.  

According to him, Lutetium 177 PSMA (Lu-177 PSMA) is a type of PRRT used for treating patients with MCRPC, who are not eligible for chemotherapy or have failed first-line chemotherapy. Numerous research studies around the world have proven that this treatment improves quality of life, slows down disease progression, and improves overall survival, with little or very tolerable side effects in most patients. 

The University of Pretoria is one of the pioneers of this treatment in the world, having done a lot of research with it since 2017. Other provinces such as the Western Cape and KwaZulu-Natal have also recently become involved with the therapy. This therapy is expensive and requires a lot of expertise. It also involves the input of a multidisciplinary team (MDT), which must at least include a nuclear medicine physician, a radiation oncologist, and a urologist. The Departments of Urology and Radiation Oncology at the UFS were also instrumental in the initiation of the therapy and form part of the MDT team at the UFS in the management of these patients.

Treatment puts department, university, and hospital on the map

Dr Evbuomwan says the ability to administer this treatment puts the department, the UFS, and the hospital on the map, alongside other top universities within and outside the country. “It also creates an avenue for us to gather data for research purposes and for publications. We are now able to offer a promising, safe, and highly efficacious therapy for patients with MCRPC in the Free State. Some of these patients no longer need to travel to other provinces to get the treatment.”

There are plans to expand the treatment to more patients – and hospital management, who were present at the first treatment, are excited and looking forward to the outcome of this current treatment.

Watch video below:

News Archive

It takes a village to raise a child
2016-06-13

Description: Valentino_Student Bursary Fund Campaign Tags: Valentino_Student Bursary Fund Campaign

Valentino Ndaba
Photo: Sonia Small

(Click on CC for subtitles)

Video
Student Bursary Fund Campaign booklet (pdf)
Donate
Student Bursary Fund Campaign launched: #FundAFuture and make a difference
Motho ke motho ka batho. A person is a person through others

Want to make a difference in the world? Here is how

South Africa has one of the most spectacular coastlines in the world. Take the ribbon of golden beaches sweeping along the shores of KwaZulu-Natal, for instance. But just beyond the kiteboards dappling the ocean and fields of swaying sugarcane lies one of the largest informal settlements in the province: Amaoti. A place where barefoot children are skipping alongside poverty, and violent crime incinerates hope.

Nonetheless, that place could not keep Valentino Ndaba from graduating at the University of the Free State (UFS), and setting her sails for post-graduate studies.

A village
It takes a village to raise a child. This African proverb ripples across Valentino’s life story. “My gran always used to say education is your eternal bread. She still says it to this day. She has always instilled in me the importance of education,” Valentino smiles. Her grandmother has been but one of several champions in Valentino’s life.

Maalthee Dayaram – a teacher at Brookdale Secondary School that Valentino attended – noticed a budding talent in the young girl’s writing. With dedicated attention and ceaseless encouragement, Mrs Dayaram helped pave the way for this young writer. “You might be talented and have potential, but having someone actually believe in you and tell you that you have potential makes such a difference,” Valentino says. “I fell in love with writing, and had an idea that writing might be my future.” Dire economic circumstances threatened to snuff out any sparks of hope from that fragile future, though.

Aided by Lungisani Indlela (a non-profit organisation that provides children in the Amaoti area with school fees, uniforms, shoes, etc), Valentino clung to faith in the power of education. With unwavering single-mindedness, she consistently earned top grades.

Description: Valentino Ndaba 2 Tags: Valentino Ndaba 2

Photo: Sonia Small

Not if, but when
“Dreaming of my future, my gran would always say to me, ‘when you go to university’ or ‘when you have graduated’, this and that will follow.” Her gran’s words proved to be prophetic. As the final matric results were published in early January 2012, Valentino received a phone call that would change her life irrevocably.

That call came from the well-known South African humanitarian, Tich Smith. “Would you be willing to go to university in another province?” Smith asked. Never having travelled beyond her immediate surroundings, Valentino’s brave answer was: “Yes.”

A few days later, she walked onto the Bloemfontein Campus of the UFS.

Changing futures

Valentino proceeded to obtain a BA degree in Media Studies and Journalism in 2014. She has now set her sights on an honours degree, and envisions pursuing a Master’s degree in creative writing overseas.

“Without the support I received, I would have been stuck without a future,” she says. “University has shaped me into a better version of myself. I’ve grown intellectually, spiritually, and emotionally.”

You can bring about the same change for other students in need. By contributing to the UFS Student Bursary Fund Campaign, you can change the future not only of individuals, but of communities and of our country as well.

The impact of your financial support reaches far beyond its monetary value. It pulls families from poverty. It sends forth experts and visionaries into the world. It sets in motion a culture of giving.

Visit our Giving page for ways to contribute.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept